Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Siegel, 2016, Cancer statistics, 2016, CA Cancer J Clin, 66, 7, 10.3322/caac.21332 Zhu, 2021, Epidemiology and genomics of prostate cancer in Asian men, Nat Rev Urol, 18, 282, 10.1038/s41585-021-00442-8 Katanoda, 2015, An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013, Jpn J Clin Oncol, 45, 390, 10.1093/jjco/hyv002 Samson, 2002, Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma, Cancer, 95, 361, 10.1002/cncr.10647 Prostate Cancer Trialists’ Collaborative Group, 2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095 Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Khalaf, 2019, Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial, Lancet Oncol, 20, 1730, 10.1016/S1470-2045(19)30688-6 Yano, 2013, Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials, Int J Clin Oncol, 18, 96, 10.1007/s10147-011-0349-5 Sternberg, 2020, Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 382, 2197, 10.1056/NEJMoa2003892 Sartor, 2014, Treatment sequencing in metastatic castrate-resistant prostate cancer, Asian J Androl, 16, 426, 10.4103/1008-682X.126378 Izumi, 2014, Optimal treatment for castration-resistant prostate cancer, Asian J Androl, 16, 498, 10.4103/1008-682X.126380 Wurnschimmel, 2021, Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups, Int J Urol, 28, 862, 10.1111/iju.14595 Izumi, 2017, Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial, BMC Cancer, 17, 677, 10.1186/s12885-017-3661-2 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Cassinello, 2021, Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: a systematic review and meta-analysis, Cancer Treat Rev, 93, 102152, 10.1016/j.ctrv.2020.102152 Kobayashi, 2020, Sequential use of androgen receptor axis-targeted agents in chemotherapy-naive castration-resistant prostate cancer: a multicenter retrospective analysis with 3-year follow-up, Clin Genitourin Cancer, 18, e46, 10.1016/j.clgc.2019.09.011 Kadono, 2016, Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy, World J Urol, 34, 261, 10.1007/s00345-015-1607-3 Scher, 2010, Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study, Lancet, 375, 1437, 10.1016/S0140-6736(10)60172-9 Matsubara, 2014, Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer, Cancer Sci, 105, 1313, 10.1111/cas.12496 Miyake, 2021, Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents, Int J Clin Oncol, 26, 1745, 10.1007/s10147-021-01956-2 Wei, 2021, Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis, Front Oncol, 11, 732599, 10.3389/fonc.2021.732599 Tagawa, 2021, Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate, Prostate Cancer Prostat Dis, 24, 1032, 10.1038/s41391-021-00318-3 Colomba, 2020, Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: natural history, management and outcome, Eur J Cancer, 129, 117, 10.1016/j.ejca.2020.01.017 Yumiba, 2017, A case of fulminant hepatitis after administration of abiraterone acetate, Hinyokika Kiyo, 63, 479